Key Drivers
- Strong Liquidity
- Persistent Losses
- Share Dilution
AIAI Summary
TNGX is now a concentrated, event-driven bet on whether vopimetostat's 92% early response signal with daraxonrasib can replicate with durable survival and acceptable safety in MTAP-deleted pancreatic cancer; its ~$1 billion liquidity runway reduces near-term financing risk, but the $4.4 billion valuation already demands convincing confirmatory data.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Share Dilution
TNGX has exceptional liquidity and low debt but remains cash-burning and unprofitable, making its high valuation dependent on future revenue growth.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Support breakdown
- •Recovery needed
TNGX remains bearish over the last month, with the break below $22.30–$22.50 shifting focus to holding $21.75, while a recovery above $23.30–$24.00 is needed to improve momentum.
Sharp drop below the prior $22.30–$22.50 support zone
Sentiment & News
Key News Insights:
- •Mixed institutional flows
- •Shares under pressure
- •No clinical catalyst
Tango Therapeutics shares fell 6.2% amid mixed institutional trading and routine investor-relations and equity-compensation updates, with no new clinical or operational catalyst disclosed.
The lack of material operating news leaves the stock susceptible to sentiment-driven volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings